LIRAGLUTIDETABLETS(LIRAGLIPTIN)Liragliptintabletsareanoralmedicationbelongingtothedipeptidylpeptidase-4(DPP-4)inhibitorclass,usedforthemanagementoftype2diabetesmellitus.Thismedicationworksbyincreasingthelevelsofincretinhormones,whichhelpregulatebloodsugarbystimulatinginsulinreleaseandreducingglucagonsecretion.Liragliptinistypicallyprescribedasanadjuncttodietandexercisetoimproveglycemiccontrolinadultswithtype2diabetes.Itmaybeusedaloneorincombinationwithotherantidiabeticagents,suchasmetforminorsulfonylureas,dependingonthepatient'sneeds.Keyfeaturesofliragliptinincludeitsonce-dailydosing,minimalriskofhypoglycemiawhenusedasmonotherapy,andafavorabletolerabilityprofile.Commonsideeffectsmayincludenasopharyngitis,headache,andupperrespiratorytractinfections.Patientswithahistoryofpancreatitisorsevererenalimpairmentshoulduseliragliptinwithcaution.Itisnotrecommendedfortype1diabetesordiabeticketoacidosis.Alwaysfollowtheprescribingphysician'sinstructionsandrefertothefullprescribinginformationfordetaileddosageguidelines,contraindications,andsafetyinformation.
